

# Jlw Lambert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/145291/publications.pdf>

Version: 2024-02-01

88  
papers

2,447  
citations

218592

26  
h-index

233338

45  
g-index

93  
all docs

93  
docs citations

93  
times ranked

4057  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1473-1481.	1.1	6
2	The Effects of Modified Intermittent Fasting in Psoriasis (MANGO): Protocol for a Two-Arm Pilot Randomized Controlled Open Cross-over Study. <i>JMIR Research Protocols</i> , 2022, 11, e26405.	0.5	3
3	Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 403-412.	1.3	10
4	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 171-185.	3.7	57
5	Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study. <i>Advances in Therapy</i> , 2022, 39, 1068-1080.	1.3	8
6	Variability drivers of treatment costs in hospitals: A systematic review. <i>Health Policy</i> , 2022, 126, 75-86.	1.4	5
7	Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. <i>British Journal of Dermatology</i> , 2022, 187, 254-256.	1.4	11
8	Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled Trial. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2375-2383.e6.	0.3	19
9	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	2.0	12
10	Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 1324-1336.	0.6	2
11	Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE 2 and 3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1275-1283.	1.3	8
12	Weighing in on weight-based secukinumab dosing for psoriasis. <i>British Journal of Dermatology</i> , 2022, , .	1.4	0
13	Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice. <i>Journal of Clinical Medicine</i> , 2022, 11, 3011.	1.0	4
14	Patient-Relevant Outcomes in Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 806.	2.0	7
15	The reliability of the Self-Assessment Cutaneous Inflammatory Disease Extent Score (SA-CIDES) and the rule of hands to assess the involved body surface area in psoriasis and eczema. <i>British Journal of Dermatology</i> , 2021, 184, 171-173.	1.4	0
16	Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry-based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	1.5	136
17	Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3326.	1.8	11
18	Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 1040.	1.0	11

#	ARTICLE	IF	CITATIONS
19	Riskâ€mitigating behaviours in people with inflammatory skin and joint disease during the COVIDâ€19 pandemic differ by treatment type: a crossâ€sectional patient survey*. British Journal of Dermatology, 2021, 185, 80-90.	1.4	26
20	Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatology and Therapy, 2021, 11, 1265-1275.	1.4	5
21	Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?. Drugs in R and D, 2021, 21, 341-350.	1.1	10
22	Describing the burden of the COVIDâ€19 pandemic in people with psoriasis: findings from a global crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e636-e640.	1.3	18
23	Comment on "An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology". Journal of the American Academy of Dermatology, 2021, 85, e89-e90.	0.6	0
24	Venous thrombotic events in psoriasis patients: a systematic review with meta-analysis. Annals of Medicine, 2021, 53, 1076-1083.	1.5	9
25	Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority studyâ€the BeNeBio study. Trials, 2021, 22, 707.	0.7	7
26	The Use of Metrics in Daily Practice and the Perception of Psoriasis-Associated Comorbidities: Discrepancies Between Research and Real-World. Psoriasis: Targets and Therapy, 2021, Volume 11, 169-175.	1.2	2
27	Teledermatology in Belgium: a pilot study. Acta Clinica Belgica, 2020, 75, 116-122.	0.5	9
28	Clinical response correlates with 4â€week postinjection ustekinumab concentrations in patients with moderateâ€toâ€severe psoriasis. British Journal of Dermatology, 2020, 182, 390-397.	1.4	11
29	Response to <sc>IL</sc>â€17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the proteinâ€coding and untranslated regions of the <sc>IL</sc>â€17A gene: results from a multicentre study of four European psoriasis cohorts. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 112-118.	1.3	17
30	Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETAâ€PSO: Belgian Evidenceâ€based Treatment Advice in Psoriasis) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 and Venereology, 2020, 34, 1654-1665.	1.3	26
31	Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETAâ€PSO: Belgian Evidenceâ€based Treatment Advice in Psoriasis) Tj ETQq1 1 0.784314 rgBT 1914-1923.	1.3	20
32	Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis. JAMA Dermatology, 2020, 156, 1344.	2.0	29
33	Realâ€life effectiveness and shortâ€term (16â€week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e837-e839.	1.3	26
34	Comparison of Personality Traits among Patients with Psoriasis, Atopic Dermatitis, and Stress: A Pilot Study. Dermatology, 2020, 236, 324-328.	0.9	3
35	A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents. JAMA Dermatology, 2020, 156, 384.	2.0	33
36	Therapeutische Patientenschulungsprogramme und UnterstÃ¼tzung beim Selbstmanagement fÃ¼r Patienten mit Psoriasis â€“ eine systematische Ãbersicht. JDDG - Journal of the German Society of Dermatology, 2019, 17, 685-697.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Learning From Success and Failure: Biologics for Non-approved Skin Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 1918.	2.2	17
38	Comparison of methods to estimate the affected body surface area and the dosage of topical treatments in psoriasis and atopic dermatitis: the advantage of a picture-based tool. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1726-1732.	1.3	1
39	Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 837-848.	1.3	71
40	Defining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step toward Personalized Therapy. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2232-2235.e1.	0.3	11
41	Therapeutic patient education and self-management support for patients with psoriasis – a systematic review. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 685-695.	0.4	12
42	Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 634-639.	1.0	8
43	Critical appraisal of the oxidative stress pathway in vitiligo: a systematic review and meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1089-1098.	1.3	62
44	Towards the development of a RNA-based topical treatment for psoriasis: Proof of concept in a 3D psoriasis skin model. <i>Experimental Dermatology</i> , 2018, 27, 463-469.	1.4	13
45	Targeting the IL-23/IL-17 Pathway in Psoriasis: the Search for the Good, the Bad and the Ugly. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 625-637.	3.3	9
46	Topically applied lipid- and surfactant-based nanoparticles in the treatment of skin disorders. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 109-122.	2.4	35
47	Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. <i>British Journal of Dermatology</i> , 2017, 177, 489-496.	1.4	55
48	Towards a bacterial treatment for armpit malodour. <i>Experimental Dermatology</i> , 2017, 26, 388-391.	1.4	40
49	In vitro psoriasis models with focus on reconstructed skin models as promising tools in psoriasis research. <i>Experimental Biology and Medicine</i> , 2017, 242, 1158-1169.	1.1	44
50	Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. <i>JAMA Dermatology</i> , 2017, 153, 1147.	2.0	75
51	Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER). <i>Journal of Dermatological Treatment</i> , 2017, 28, 394-400.	1.1	11
52	Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 294-303.	1.3	12
53	Elevated p63 Levels Facilitate Epidermal and Biliary Oncogenic Transformation. <i>Journal of Investigative Dermatology</i> , 2017, 137, 494-505.	0.3	25
54	JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases. <i>PLoS ONE</i> , 2016, 11, e0164080.	1.1	143

#	ARTICLE	IF	CITATIONS
55	Exploring the feasibility of whole blood to identify systemic miRNA biomarkers for patients with moderate to severe psoriasis. <i>European Journal of Dermatology</i> , 2016, 26, 195-198.	0.3	6
56	Characterization data on the topical carrier DDC642. <i>Data in Brief</i> , 2016, 7, 1204-1210.	0.5	6
57	A multileveled approach in psoriasis assessment and follow-up: A proposal for a tailored guide for the dermatological practice. <i>Journal of Dermatological Treatment</i> , 2016, 27, 298-310.	1.1	9
58	Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. <i>Nature Genetics</i> , 2016, 48, 1418-1424.	9.4	225
59	Pyoderma gangrenosum with granuloma formation: not always a benign disorder. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 188-189.	1.3	4
60	Contact dermatitis in patients undergoing serial intravitreal injections. <i>Contact Dermatitis</i> , 2016, 74, 18-21.	0.8	16
61	Analysis of telomere length as predictive marker in psoriasis for comorbidities. <i>Experimental Dermatology</i> , 2016, 25, 388-390.	1.4	4
62	Clinical Significance of Serum Soluble CD Molecules to Assess Disease Activity in Vitiligo. <i>JAMA Dermatology</i> , 2016, 152, 1194.	2.0	26
63	FRT - FONDATION RENE TOURAINE. <i>Experimental Dermatology</i> , 2016, 25, 917-932.	1.4	0
64	The many faces of interleukin-17 in inflammatory skin diseases. <i>British Journal of Dermatology</i> , 2016, 175, 892-901.	1.4	75
65	An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: Proof-of-concept in the treatment of psoriasis. <i>International Journal of Pharmaceutics</i> , 2016, 500, 268-274.	2.6	56
66	Psoriasis: burning down the host. <i>Journal of Dermatological Treatment</i> , 2016, 27, 1-1.	1.1	8
67	Measuring the Impact of Vitiligo: Behind the White Spots. <i>Journal of Investigative Dermatology</i> , 2016, 136, 6-7.	0.3	2
68	Chronic and Invasive Fungal Infections in a Family with CARD9 Deficiency. <i>Journal of Clinical Immunology</i> , 2016, 36, 204-209.	2.0	98
69	Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective. <i>Journal of Dermatological Treatment</i> , 2016, 27, 128-133.	1.1	5
70	Secukinumab: IL-17A inhibition to treat psoriatic arthritis. <i>Drugs of Today</i> , 2016, 52, 607.	0.7	8
71	Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2349-2355.	1.3	33
72	Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?. <i>Journal of Dermatological Treatment</i> , 2015, 26, 520-527.	1.1	11

#	ARTICLE	IF	CITATIONS
73	Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis. <i>JAMA Dermatology</i> , 2015, 151, 616.	2.0	75
74	micro RNA s in psoriasis: leaders or followers?. <i>British Journal of Dermatology</i> , 2015, 173, 323-323.	1.4	6
75	Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1723-1731.	1.3	19
76	Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 22-32.	1.3	22
77	Profile of the Belgian dermatologist: results of an online survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 667-668.	1.3	0
78	Targeted silencing of DEFB4 in a bioengineered skin-humanized mouse model for psoriasis: development of siRNA SECosome-based novel therapies. <i>Experimental Dermatology</i> , 2014, 23, 199-201.	1.4	47
79	Viewpoint on handling anti-TNF failure in psoriasis. <i>Archives of Dermatological Research</i> , 2013, 305, 945-950.	1.1	10
80	Identification of miR-145 as a Key Regulator of the Pigmentary Process. <i>Journal of Investigative Dermatology</i> , 2013, 133, 201-209.	0.3	99
81	Identifying targets for topical RNAi therapeutics in psoriasis: assessment of a new in vitro psoriasis model. <i>Archives of Dermatological Research</i> , 2013, 305, 501-512.	1.1	35
82	miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. <i>International Journal of Oncology</i> , 2013, 42, 1443-1451.	1.4	76
83	A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results. <i>Archives of Dermatological Research</i> , 2011, 303, 57-63.	1.1	28
84	Flexible Nanosomes (SECosomes) Enable Efficient siRNA Delivery in Cultured Primary Skin Cells and in the Viable Epidermis of Ex Vivo Human Skin. <i>Advanced Functional Materials</i> , 2010, 20, 4077-4090.	7.8	79
85	Serum plakophilin-3 autoreactivity in paraneoplastic pemphigus. <i>British Journal of Dermatology</i> , 2010, 163, 630-632.	1.4	19
86	Cutaneous short-interfering RNA therapy. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 1333-1349.	2.4	61
87	Knockdown of Myosin Va Isoforms by RNAi as a Tool to Block Melanosome Transport in Primary Human Melanocytes. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2474-2484.	0.3	30
88	The Dilute Locus and Griscelli Syndrome: Gateways Towards a Better Understanding of Melanosome Transport. <i>Pigment Cell &amp; Melanoma Research</i> , 2001, 14, 320-327.	4.0	34